Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
Would you offer BM biopsy as the next step for progressive thrombocytosis when peripheral blood is negative for JAK2, CALR, and MPL mutations for MPN diagnosis?
How do you choose between peginterferon and anagrelide for ET patients if hydroxyurea-intolerant?
How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?
Is bone marrow biopsy indicated in patients with primary polycythemia but negative for JAK2 mutation including exon 12?
Would you offer radiation therapy for extramedullary testicular masses in the setting of multiple myeloma?
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
How do you discuss harms of MGUS screening with other medical providers?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
For patients with solitary plasmacytoma of the ureter undergoing definitive XRT (40-50 Gy), what dose constraint do you use for the ureter?
What induction would you choose for a healthy 65 year old with prior chemo/RT for H&N cancer 2 years ago, now with FLT3-ITD+ (0.25) and inv(16) AML?